All News

Article

Exploring Idiopathic Myopathies

2026 EULAR Press Release Jun 05, 2026

Idiopathic inflammatory myopathies (IIM) are a heterogenous group of autoimmune conditions with substantial morbidity. EULAR in collaboration with the American College of Rheumatology (ACR) introduced classification criteria for the major subgroups in 2017,1 but there is a need for contemporary real-world data to understand the burden – and well as new ways of assessing disease activity.

AI use in rheumatology is probably going to be used the first in musculoskeletal imaging. Since patients journey is digitalised. #EULAR2026 @RheumNow We are drowning in healthcare data. https://t.co/61HqtSCQxC

#EULAR2026 POS0306 Can we predict #lupus nephritis pts who would achieve CR at 12 mths? Monocentric study used M.Learning: developed & internally validated 5 Clinical Score (LUPRED) with AUC 0.75 training set, 0.78 validation. Simple to use but needs external validation @RheumNow https://t.co/1VRE1yBCac

https://x.com/Yuz6Yusof/status/2062886696459346275/photo/1

Digitalization in rheumatology. How can it help? Potential opportunities @RheumNow #EULAR2026 https://t.co/KKImSNLgbq

Rapcabtagene Autoleucel -YTB323 rapidly manufactured CD19 CAR T #POS0303 #EULAR2026 @RheumNow 24 months follow up data for 21 pts. Durable b cell reduction and decrease in disease activity. https://t.co/m3lYjZJJIy

Hypertension was the most robust and consistent predictor of pre term labor. Data from germany nationwide #POS1062 @RheumNow ##EULAR2026 https://t.co/Uccf11PpAK

https://x.com/bella_mehta/status/2062867804408218013/photo/1

Sarcoidosis increases the risk of MGUS and multiple myeloma. Propensity matched Data from a large global collaborative network study with 40k pts. POS0231 #EULAR2026 @RheumNow https://t.co/mygYCjigFV

https://x.com/bella_mehta/status/2062861627444404540/photo/1

What do you think about this cartoon-style format for posters? A- I love it! B- It’s Ok but I prefer classic As for the content: Axia digital therapeutic app improves mobility, BASDAI, sleep an sexual function in 32 patients #POS0199 #EULAR2026 @rheumnow https://t.co/mV83dMF4vi

https://x.com/Nellziade/status/2062847138959081686/photo/1

Which imaging test has the highest carbon footprint??? Think wisely before prescribing 🩻 #EULAR2026 @RheumNow https://t.co/36Ej8smWRd

https://x.com/Nellziade/status/2062844472522666061/photo/1

Did you take part in #RheumaVision this year? @cristianasieiro takes us through the past, present & future of this innovative initiative, which held its final yesterday at #EULAR2026. You can watch all the videos online- and be sure to participate next year! @EMEUNET @RheumNow https://t.co/liWzYYbIxI

https://x.com/DrMiniDey/status/2062843422172385751/photo/1

#RheumMadness comes to #EULAR2026! Dr David Leverenz takes us through the background and process of this firm favourite in rheum education. An excellent example of gamification for medical education more broadly. @RheumNow https://t.co/lmgkJbTgBm

https://x.com/DrMiniDey/status/2062842842406375826/photo/1

Another reason for NOT prescribing ANA (and other tests) as a “screening” test when not indicated: High carbon footprint! #EULAR2026 @rheumnow https://t.co/BAuzQuZ0Iv

https://x.com/Nellziade/status/2062841554012610987/photo/1

Have you ever thought of diclofenac as an environmental pollutant? Interesting insights from the carbon footprint of #rheumatology session at #EULAR2026 @rheumnow https://t.co/RJWB6DmiZh

https://x.com/Nellziade/status/2062833468040482919/photo/1

Understanding how Bispecific T cell engagers work: remarkable mode of action! Let’s hope it works as well as in oncology! #teclistamab in #SSc #HOT session Pr Oliver Distler #EULAR2026 @RheumNow https://t.co/waSCXKA79Y

Management of rheumatologic immune-related adverse events (irAEs), inflammatory conditions triggered by immune checkpoint inhibitor (ICI) cancer therapy Abstr OP0358 @RheumNow #EULAR2026 https://t.co/hnU7L7RnU8

https://x.com/synovialjoints/status/2062818769081192639/photo/1

103 patients with ICI-induced inflammatory arthritis. 37.9% died during follow-up. Maximum prednisone dose above 20mg to treat rheumatologic immune-related adverse events was associated with significantly worse overall survival HR 2.35 (95% CI 1.18–4.69, p=0.015). Cumulative https://t.co/vAmIAH7B64

https://x.com/synovialjoints/status/2062814501867565297/photo/1

RheumNow’s expanded coverage of the #EULAR2026 annual meeting is sponsored by Bristol Myers Squibb and UCB. RheumNow and its faculty independently select all coverage content.

Proud to present POS0784 at #EULAR2026. RheumACaN education + pathway redesign across primary and secondary care improved early inflammatory arthritis referrals within 3 working days from 52% to 70%, exceeding the national benchmark. 95% of clinicians changed their practice. https://t.co/W6VViVRndp

https://x.com/synovialjoints/status/2062588940922552789/photo/1

DAY 1 & 2 Recap: EULAR 2026 Highlights https://t.co/uVMerChWN6

Dr. John Cush

@RheumNow HOT #Obesity session (7) 📢A call for action Current RMD treatments ignore obesity: They all target immune response but miss the metabolic-inflammatory loop Breaking that cycle may be the missing piece Obesity must be part of every rheumatology plan #EULAR2026 @rheumnow

Topics

All News

Exploring Idiopathic Myopathies

Do you get our email newsletter?